First Horizon Advisors, Inc. Aerie Pharmaceuticals Inc Transaction History

First Horizon Advisors, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 09, 2022	SELL	$7.02 - $13.33 $1,804 - $3,425	-257 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$11.32 - $16.63 $1,811 - $2,660	160 Added 164.95%	257 $2,000
Q3 2021 Nov 09, 2021	BUY	$11.32 - $16.63 $1,098 - $1,613	97 New	97 $1,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on First Horizon Advisors, Inc. with notifications on news.